VIDEO: Phase 2 study compares two preparations of ABBV-RGX-314

ByDavid A. Eichenbaum, MD

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, David A. Eichenbaum, MD, discusses data on ABBV-RGX-314 for neovascular age-related macular degeneration.

The phase 2 study looked at low-dose and high-dose ABBV-RGX-314 (Regenxbio, AbbVie) prepared through the research-oriented Hyperstack process and the commercially oriented bioreactor process.

“Both the Hyperstack-produced 314 and the bioreactor-produced 314 have similar safety and efficacy through the date of our data cutoff in this phase 2 study,” Eichenbaum said.

Published by:

Sources/Disclosures

Collapse

Source:

Eichenbaum D. Subretinal delivery of RGX-314 for neovascular AMD: A phase 2 pharmacodynamic study. Presented at: Angiogenesis, Exudation, and Degeneration 2024; Feb. 3, 2024 (virtual meeting).

Disclosures: Eichenbaum reports being an investigator and consultant for Regenxbio and a speaker, investigator and consultant for AbbVie.

Angiogenesis, Exudation and Degeneration Meeting

Read more

VIDEO: Phase 2 study compares two preparations of ABBV-RGX-314

Related Content